Linda Vahdat, MD, MBANewYork-Presbyterian/Weill Cornell MedicineNewswise — Dr. Vahdat is an attending physician at NewYork-Presbyterian and the director of the Breast Cancer Research Program at Weill Cornell Medicine, as well as the co-leader of the Breast Cancer Program within the Meyer Cancer Center. While she is a translational breast cancer medical oncologist, Dr. Vahdat’s expertise is drug development. She has been involved in the identification, conceptualization, design and execution of Phase 0 through III clinical trials of new therapies in high-risk adjuvant and metastatic breast cancer patients since 1994. Dr. Vahdat has led two separate drug development efforts that led to the FDA approval of two leading drugs to fight metastatic breast cancer, and her team has taken the lead for at least two other drugs that have a high probability of success, both in triple negative breast cancer.

Dr. Vahdat is a participant in the following studies and trials being presented at SABCS: - Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results- A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)- A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Dawn Hershman, MD, MSNewYork-Presbyterian/Columbia University Medical Center Dr. Hershman is the leader of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Medical Center and is nationally recognized for her expertise in breast cancer treatment, prevention and survivorship. She has several national leadership roles in oncology.

Dr. Hershman is the co-investigator for the following research being presented at SABCS: - Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202)

Dr. Hershman will also be a discussant for poster four on Wednesday, December 8, about survivorship.

Kevin Kalinsky, MD, MSNewYork-Presbyterian/Columbia University Medical Center Dr. Kalinsky cares for patients diagnosed with breast cancer and is an assistant professor of medicine. His research involves the development of early phase clinical trials to assess novel therapeutic agents in breast cancer based on tumor genomics. The goal of his research is to translate findings developed at the bench to clinical trials for study at the bedside.

Dr. Kalinsky is presenting a number of posters at SABCS, including:- Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer undergoing neoadjuvant chemotherapy- Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer- A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation- . Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results- Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC)

Tessa Cigler, MD, MPHNewYork-Presbyterian/Weill Cornell Medicine Dr. Cigler is a medical oncologist dedicated to treating and preventing breast cancer. She is a strong believer in the benefits of a multidisciplinary approach to breast cancer care and pays careful attention to the short and long term effects of diagnosis and treatment on physical and emotional well-being. Dr. Cigler is an active clinical investigator and heads several clinical trials designed to provide her patients with access to the newest and most promising options for therapy.

Dr. Cigler is a participant in the following studies and trials being presented at SABCS: - Body image in women with breast cancer using a scalp cooling system to reduce chemotherapy induced alopecia- Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer

MEDIA CONTACT
Register for reporter access to contact details